Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
Identifieur interne : 001600 ( Istex/Corpus ); précédent : 001599; suivant : 001601Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
Auteurs : Rodger J. Elble ; Oksana Suchowersky ; Stephanie Shaftman ; William J. Weiner ; Peng Huang ; Barbara TilleySource :
- Movement Disorders [ 0885-3185 ] ; 2010-06-15.
English descriptors
Abstract
We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double‐blind placebo‐controlled futility trial of coenzyme Q10 and GPI‐1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22997
Links to Exploration step
ISTEX:7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name><affiliation><mods:affiliation>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation><mods:affiliation>Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada</mods:affiliation></affiliation></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation><mods:affiliation>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation><mods:affiliation>Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation><mods:affiliation>Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22997</idno><idno type="url">https://api.istex.fr/document/7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001600</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name><affiliation><mods:affiliation>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation><mods:affiliation>Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada</mods:affiliation></affiliation></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</mods:affiliation></affiliation></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation><mods:affiliation>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation><mods:affiliation>Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation><mods:affiliation>Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-06-15">2010-06-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1082">1082</biblScope><biblScope unit="page" to="1086">1086</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422</idno><idno type="DOI">10.1002/mds.22997</idno><idno type="ArticleID">MDS22997</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>Unified Parkinson's Disease Rating Scale</term><term>bias</term><term>clinical trial</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double‐blind placebo‐controlled futility trial of coenzyme Q10 and GPI‐1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Rodger J. Elble MD, PhD</name><affiliations><json:string>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA</json:string></affiliations></json:item><json:item><name>Oksana Suchowersky MD</name><affiliations><json:string>Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada</json:string></affiliations></json:item><json:item><name>Stephanie Shaftman MSc, MS</name><affiliations><json:string>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</json:string><json:string>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</json:string></affiliations></json:item><json:item><name>William J. Weiner MD</name><affiliations><json:string>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA</json:string></affiliations></json:item><json:item><name>Peng Huang PhD</name><affiliations><json:string>Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA</json:string></affiliations></json:item><json:item><name>Barbara Tilley PhD</name><affiliations><json:string>Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>bias</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinical trial</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Unified Parkinson's Disease Rating Scale</value></json:item></subject><language><json:string>eng</json:string></language><abstract>We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double‐blind placebo‐controlled futility trial of coenzyme Q10 and GPI‐1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>6.2</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>670</abstractCharCount><pdfWordCount>10987</pdfWordCount><pdfCharCount>73123</pdfCharCount><pdfPageCount>20</pdfPageCount><abstractWordCount>100</abstractWordCount></qualityIndicators><title>Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease</title><corporate><json:item><name></name><affiliations><json:string>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA</json:string><json:string>Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada</json:string><json:string>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</json:string><json:string>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</json:string><json:string>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA</json:string><json:string>Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA</json:string><json:string>Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas, USA</json:string></affiliations></json:item></corporate><genre><json:string>Serial article</json:string></genre><host><volume>25</volume><pages><total>5</total><last>1086</last><first>1082</first></pages><issn><json:string>0885-3185</json:string></issn><issue>8</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22997</json:string></doi><id>7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note><note>NIH (National Institute of Neurological Disorders and Stroke) - No. U01NS043127; No. U01NS 043128; No. U10NS44415; No. 4455;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease</title><author><orgName>On Behalf of the NINDS NET‐PD Investigators</orgName><affiliation>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA</affiliation><affiliation>Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada</affiliation><affiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</affiliation><affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</affiliation><affiliation>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA</affiliation><affiliation>Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA</affiliation><affiliation>Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas, USA</affiliation></author><author><persName><forename type="first">Rodger J.</forename><surname>Elble</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL</p></note><affiliation>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA</affiliation></author><author><persName><forename type="first">Oksana</forename><surname>Suchowersky</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada</affiliation></author><author><persName><forename type="first">Stephanie</forename><surname>Shaftman</surname><roleName type="degree">MSc, MS</roleName></persName><affiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</affiliation><affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</affiliation></author><author><persName><forename type="first">William J.</forename><surname>Weiner</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA</affiliation></author><author><persName><forename type="first">Peng</forename><surname>Huang</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA</affiliation></author><author><persName><forename type="first">Barbara</forename><surname>Tilley</surname><roleName type="degree">PhD</roleName></persName><affiliation>Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-06-15"></date><biblScope unit="vol">25</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1082">1082</biblScope><biblScope unit="page" to="1086">1086</biblScope></imprint></monogr><idno type="istex">7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422</idno><idno type="DOI">10.1002/mds.22997</idno><idno type="ArticleID">MDS22997</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double‐blind placebo‐controlled futility trial of coenzyme Q10 and GPI‐1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>bias</term></item><item><term>clinical trial</term></item><item><term>Unified Parkinson's Disease Rating Scale</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-05-01">Received</change><change when="2009-12-11">Registration</change><change when="2010-06-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="80"><doi origin="wiley" registered="yes">10.1002/mds.v25:8</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">8</numbering></numberingGroup><coverDate startDate="2010-06-15">15 June 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="170" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22997</doi><idGroup><id type="unit" value="MDS22997"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-05-01"></event><event type="manuscriptRevised" date="2009-10-08"></event><event type="manuscriptAccepted" date="2009-12-11"></event><event type="firstOnline" date="2010-02-03"></event><event type="publishedOnlineFinalForm" date="2010-06-09"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-02-03"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1082</numbering><numbering type="pageLast">1086</numbering></numberingGroup><correspondenceTo>Department of Neurology, Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL</correspondenceTo><objectNameGroup><objectName elementName="appendix">APPENDIX</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22997.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="6"></count><count type="wordTotal" number="3275"></count></countGroup><titleGroup><title type="main" xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease<link href="#fn3"></link></title><title type="short" xml:lang="en">Impact of Belief in Neuroprotection</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Rodger J.</givenNames><familyName>Elble</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>relble@siumed.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Oksana</givenNames><familyName>Suchowersky</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3 #af4"><personName><givenNames>Stephanie</givenNames><familyName>Shaftman</familyName><degrees>MSc, MS</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af5"><personName><givenNames>William J.</givenNames><familyName>Weiner</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Peng</givenNames><familyName>Huang</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Barbara</givenNames><familyName>Tilley</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af7" noteRef="#fn4"><groupName>On Behalf of the NINDS NET‐PD Investigators </groupName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="CA" type="organization"><unparsedAffiliation>Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="CA" type="organization"><unparsedAffiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">bias</keyword><keyword xml:id="kwd3">clinical trial</keyword><keyword xml:id="kwd4">Unified Parkinson's Disease Rating Scale</keyword></keywordGroup><fundingInfo><fundingAgency>NIH (National Institute of Neurological Disorders and Stroke)</fundingAgency><fundingNumber>U01NS043127</fundingNumber><fundingNumber>U01NS 043128</fundingNumber><fundingNumber>U10NS44415</fundingNumber><fundingNumber>4455</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double‐blind placebo‐controlled futility trial of coenzyme Q<sub>10</sub> and GPI‐1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn3"><p>Potential conflict of interest: Nothing to report.</p></note><note xml:id="fn4"><p>Members of the “NET‐PD Steering Committee” are listed as an Appendix.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Impact of Belief in Neuroprotection</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Rodger J.</namePart><namePart type="family">Elble</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA</affiliation><description>Correspondence: Department of Neurology, Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Oksana</namePart><namePart type="family">Suchowersky</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stephanie</namePart><namePart type="family">Shaftman</namePart><namePart type="termsOfAddress">MSc, MS</namePart><affiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</affiliation><affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">William J.</namePart><namePart type="family">Weiner</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Peng</namePart><namePart type="family">Huang</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Barbara</namePart><namePart type="family">Tilley</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>On Behalf of the NINDS NET‐PD Investigators</namePart><affiliation>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA</affiliation><affiliation>Department of Medical Genetics, University of Calgary, Calgary, Alberta, Canada</affiliation><affiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada</affiliation><affiliation>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA</affiliation><affiliation>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA</affiliation><affiliation>Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA</affiliation><affiliation>Division of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas, USA</affiliation><description>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USADepartment of Medical Genetics, University of Calgary, Calgary, Alberta, CanadaDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, CanadaDepartment of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USADepartment of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USADepartment of Oncology, Johns Hopkins University, Baltimore, Maryland, USADivision of Biostatistics, University of Texas Health Science Center School of Public Health, Houston, Texas, USA</description></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-06-15</dateIssued><dateCaptured encoding="w3cdtf">2009-05-01</dateCaptured><dateValid encoding="w3cdtf">2009-12-11</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">6</extent><extent unit="words">3275</extent></physicalDescription><abstract lang="en">We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double‐blind placebo‐controlled futility trial of coenzyme Q10 and GPI‐1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><note type="funding">NIH (National Institute of Neurological Disorders and Stroke) - No. U01NS043127; No. U01NS 043128; No. U10NS44415; No. 4455; </note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>bias</topic><topic>clinical trial</topic><topic>Unified Parkinson's Disease Rating Scale</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1082</start><end>1086</end><total>5</total></extent></part></relatedItem><identifier type="istex">7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422</identifier><identifier type="DOI">10.1002/mds.22997</identifier><identifier type="ArticleID">MDS22997</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001600 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001600 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:7B582BB89ABB2925C058C7CDDC8ABF2C1BED2422
|texte= Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |